# Gestational Diabetes Mellitus in Singleton and Twin Pregnancies: A Comparison of Fetomaternal Outcomes

**Authors:** Selina Balke, Izabela A. Kotzott, Annette Aigner, Petra Weid, Wolfgang Henrich, Joachim W. Dudenhausen, Josefine T. Königbauer

PMC · DOI: 10.3390/diagnostics16040632 · 2026-02-22

## TL;DR

This study compares the effects of gestational diabetes in twin and singleton pregnancies, finding differences in insulin use and fetal growth outcomes.

## Contribution

The study provides new insights into how gestational diabetes affects twin pregnancies differently than singleton pregnancies, particularly in insulin requirements and fetal growth.

## Key findings

- Women with gestational diabetes in twin pregnancies required insulin less frequently than those in singleton pregnancies.
- Twin pregnancies were more likely to result in intrauterine growth restriction and small-for-gestational-age neonates compared to singleton pregnancies.
- Large-for-gestational-age neonates were not observed in twin pregnancies, unlike in singleton pregnancies.

## Abstract

Background: Gestational diabetes mellitus (GDM) complicates a significant number of pregnancies and is associated with both short- and long-term risks for the mother and child. Twin pregnancies are inherently high risk, and the coexistence of GDM may amplify these risks. While the effects of GDM in singleton pregnancies have been widely studied, data on its impact in twin gestations remain limited. The aim of this study was to determine differences regarding metabolic characteristics, treatment requirements, and maternal as well as fetal outcomes between twin and singleton pregnancies with GDM to contribute to improved perinatal care. Methods: This retrospective study included obstetric data from 73 twin pregnancies (146 neonates) and 1664 singleton pregnancies with a GDM diagnosis at a tertiary perinatal center in Berlin, Germany, between 2015 and 2022. Baseline characteristics and perinatal outcomes were assessed. Adjusted multiple linear and logistic regression analyses were used for group comparisons. Results: Women with GDM in twin and singleton pregnancies exhibited comparable glucose values in the 75 g oral glucose tolerance test (OGTT) (median fasting: 95 vs. 96 mg/dL; 1 h: 183 vs. 183 mg/dL; 2 h: 144 vs. 139 mg/dL). Despite this, insulin therapy was required significantly less often in twin (5.5%) compared to singleton pregnancies (22.3%) (OR = 0.86; 95% CI: 0.78–0.96). Among insulin-treated women, combined insulin therapy was most common in twins (75%), while singleton mothers most frequently received long-acting insulin alone (61.7%), followed by combined therapy (31.3%) and short-acting insulin alone (7%). Birthweight was significantly lower in twins (β = –0.83 kg; 95% CI: –0.98 to –0.69), and when evaluated using twin-based growth standards, twins were more likely to be classified as having intrauterine growth restriction (IUGR, <3rd percentile) (OR = 3.37; 95% CI: 0.96–9.11), being small for gestational age (SGA, <10th percentile) (OR = 2.50; 95% CI: 1.23–4.76), or having a birthweight below the 30th percentile (OR = 6.11; 95% CI: 3.49–11.12). No large-for-gestational-age (LGA, >90th percentile) neonates were observed in the twin group. Conclusions: GDM manifests differently in twin and singleton pregnancies. Despite similar OGTT values, twin mothers require insulin less frequently. Growth-related complications such as IUGR and SGA are significantly more frequent in twins, likely reflecting the physiological constraints of multiple gestations rather than GDM itself. Conversely, LGA is predominantly a concern in singleton pregnancies. These findings underscore the need for individualized diagnostic criteria and management strategies for GDM in twin pregnancies.

## Linked entities

- **Diseases:** Gestational diabetes mellitus (MONDO:0005406), intrauterine growth restriction (MONDO:0005030)

## Full-text entities

- **Genes:** CSH2 (chorionic somatomammotropin hormone 2) [NCBI Gene 1443] {aka CS-2, CSB, GHB1, PL, hCS-B}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, LGALS1 (galectin 1) [NCBI Gene 3956] {aka GAL1, GBP}
- **Diseases:** hypertensive disorders (MESH:D006973), Shoulder dystocia (MESH:D000080883), acid-base disturbances (MESH:D000137), Acidosis (MESH:D000138), insulin resistance (MESH:D007333), disorder of placental implantation (MESH:D010922), Preterm birth (MESH:D047928), gestational hypertension (MESH:D046110), hypoglycemia (MESH:D007003), insulin dependency (MESH:D003922), prematurity (MESH:C536271), OGCT (MESH:C537770), intrauterine fetal death (MESH:D005313), stillbirth (MESH:D050497), maternal (MESH:D000079262), glucose intolerance (MESH:D018149), growth discrepancies (MESH:D006130), IUGR (MESH:D005317), injury to (MESH:D014947), labor (MESH:D048949), Preeclampsia (MESH:D011225), Diabetes (MESH:D003920), GDM (MESH:D016640), obesity (MESH:D009765), weight gain (MESH:D015430)
- **Chemicals:** glucose (MESH:D005947), short-acting insulin (MESH:D061266), blood glucose (MESH:D001786), insulin (MESH:D007328), long-acting insulin (MESH:D049528)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12939607/full.md

---
Source: https://tomesphere.com/paper/PMC12939607